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Note
Incorporating Cost into the Return of Incidental
Findings Calculus: Defining a Responsible
Default for Genetics and Genomics Researchers
Emily Scholtes*
Sandy Cohen lost both her mother and grandmother to
1
breast cancer. Fearing that she would also become a victim of
2
breast cancer, Sandy underwent genetic testing. The testing
3
revealed that Sandy had a BRCA1 mutation. Approximately
fifty-five to sixty-five percent of women who inherit a BRCA1
mutation will develop breast cancer sometime during their
4
lives. Genetics and genomics research led to the discovery of
5
the BRCA1 gene mutation. Because of this discovery, women
6
like Sandy Cohen are now empowered to take life-saving precautions to prevent the development of breast cancer.
* J.D. Candidate 2016, University of Minnesota Law School; B.A. 2013,
University of Northern Iowa. Thank you to Professor Susan Wolf for her invaluable feedback and guidance. Additional thanks to Sam Bolstad, Jonathan
Grant, and Joey Dobson for their comments and to the editors and staff of the
Minnesota Law Review for their tireless efforts. Finally, I must thank my family and friends for their unending support, patience, and love. Preparation of
this Note was supported in part by National Institutes of Health (NIH), National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI) Grant #1-R01-CA154517 (Gloria Petersen, Barbara Koenig, Susan M. Wolf, Principal Investigators) and aided by research conducted for that
project under the supervision of Professor Wolf. All views expressed are those
of the author and not necessarily the views of NIH, NCI, or NHGRI. Copyright
© 2016 by Emily Scholtes.
1. Basser Research Ctr. for BRCA, Patient Stories, PENN MEDICINE
ABRAMSON CANCER CTR., https://cancer.pennmedicine.org/about/patient
-stories/brca-sandy (last visited Nov. 30, 2015).
2. Id.
3. Id.
4. BRCA1 and BRCA2: Cancer Risk and Genetic Testing Fact Sheet,
NAT’L CANCER INST., http://www.cancer.gov/about-cancer/causes-prevention/
genetics/brca-fact-sheet (last visited Nov. 30, 2015).
5. See David Botstein & Neil Risch, Discovering Genotypes Underlying
Human Phenotypes: Past Successes for Mendelian Disease, Future Approaches
for Complex Disease, 33 NATURE GENETICS 228, 229 (2003).
6. See Angelina Jolie, Opinion, My Medical Choice, N.Y. TIMES (May 14,
2013), http://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html.
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Now, imagine that Sandy Cohen did not receive genetic
testing, but rather enrolled as a participant in a genomics research study. The researchers are studying colon cancer. When
the researchers sequence Sandy’s genome, they stumble upon
the BRCA1 gene mutation. They were not looking for the
BRCA1 gene mutation and this mutation is not related to the
study. Do the researchers have an ethical or legal duty to offer
these results to Sandy? This example illustrates the “vigorous
7
debate” over researchers’ duty to return individual research
results and incidental findings to research participants. An incidental finding, also known as a secondary finding, is “a finding concerning an individual research participant that has potential health or reproductive importance and is discovered in
the course of conducting research but is beyond the aims of the
8
study.” The debate over returning incidental findings has been
9
a hot topic in medical and legal circles for many years and is
10
described as “one of the thorniest current challenges.” Currently, no federal or state laws regulate the disclosure of these
11
findings. Although many agree that ethical duties arise in re12
turning certain individual results and incidental findings, the
13
legal implications are much more opaque. This legal ambigui7. Laura M. Beskow & Wylie Burke, Offering Individual Genetic Research Results: Context Matters, 2 SCI. TRANSLATIONAL MED. 1, 1 (2010).
8. Susan M. Wolf et al., Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations, 36 J.L. MED. & ETHICS 219,
219 (2008) [hereinafter Wolf et al., Managing Incidental Findings]. An incidental finding is not the same as an individual research result. Simply stated,
if the researcher was looking for the finding, then the finding is an individual
research result; if not, then the finding is an incidental finding. Erik Parens et
al., Incidental Findings in the Era of Whole Genome Sequencing?, 43
HASTINGS CTR. REP. 16, 18 (2013).
9. See Marianna J. Bledsoe et al., Return of Research Results from Genomic Biobanks: Cost Matters, 15 GENETICS MED. 103, 103 (2013).
10. Gina Kolata, Genes Now Tell Doctors Secrets They Can’t Utter, N.Y.
TIMES (Aug. 25, 2012), http://www.nytimes.com/2012/08/26/health/research/
with-rise-of-gene-sequencing-ethical-puzzles.html (quoting Francis Collins,
Director of the National Institutes of Health).
11. See Amy L. McGuire et al., Can I Be Sued for That? Liability Risk and
the Disclosure of Clinically Significant Genetic Research Findings, 24 GENOME
RES. 719, 719 (2014) (“Yet, no United States regulations directly address this
issue, and there is no clear case law to rely on.”); Susan M. Wolf, The Role of
Law in the Debate over Return of Research Results and Incidental Findings:
The Challenge of Developing Law for Translational Science, 13 MINN. J.L. SCI.
& TECH. 435, 436 (2012) [hereinafter Wolf, Role of Law] (“There is no law directly on point.”).
12. See Elizabeth R. Pike et al., Finding Fault? Exploring Legal Duties To
Return Incidental Findings in Genomic Research, 102 GEO. L.J. 795, 809
(2014).
13. See Wolf, Role of Law, supra note 11, at 437.
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ty raises concerns as ethical recommendations for researchers
evolve and seem to establish a standard of care for the research
14
enterprise. An established standard of care may lead to legal
15
liability for researchers.
Researchers may bear the additional costs that the threats
16
of liability and legal ambiguity impose. Numerous questions
17
arise. What results should be disclosed to participants? Who
should disclose the results? Who should pay for the results?
How long does a potential duty last? What are the potential
costs if researchers do not return incidental findings? The cost
and resource implications of a duty to return incidental findings may severely inhibit the advancement of genetics and genomics research and threaten the societal benefit of continued
18
research. Furthermore, as researchers continue to identify
new genetic and genomic variants, researchers will discover
more incidental findings and the costs of returning these re19
sults will likely increase. Therefore, an informed analysis of
the medical, legal, and economic implications is needed now to
ensure appropriate standards are created.
Compounding this issue are funding concerns that jeopard20
ize future research efforts and life-saving discoveries. These
14. See Ellen Wright Clayton & Amy L. McGuire, The Legal Risks of Returning Results of Genomics Research, 14 GENETICS MED. 473, 473 (2012).
15. Id.
16. See Susanne B. Haga & Jennifer Q. Zhao, Stakeholder Views on Returning Research Results, in 84 ADVANCES IN GENETICS 42, 68–69 (Theodore
Friedmann et al. eds., 2013).
17. See, e.g., KAREN H. ROTHENBERG & LYNN WEIN BUSH, THE DRAMA OF
DNA: NARRATIVE GENOMICS 3 (2014) (“Controversial issues abound—such as
determining whether, what, to whom, when and how genomic information
should be disclosed to individuals . . . .”); Clayton & McGuire, supra note 14.
18. See Gail P. Jarvik et al., Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices in Between, 94 AM. J. HUM. GENETICS 818, 820 (2014); Michael R. Ulrich, Resource Restraints: Rethinking
Disclosure of Individual Genomic Findings, 17 MICH. ST. U. J. MED. & L. 127,
145 (2012) (“With all of the good that has come from conducting research and
all the potential discoveries that lie in wait in genomic research it is vital that
a suitable obligation to return individual results be clarified.”).
19. See Bledsoe et al., supra note 9, at 104.
20. Sam Stein, House GOP Votes Down NIH Funding Measure One Day
After Members Praised NIH Funding, HUFFINGTON POST (Mar. 19, 2015),
http://www.huffingtonpost.com/2015/03/19/nih-funding-_n_6901932.html; Liz
Szabo, NIH Director: Budget Cuts Put U.S. Science at Risk, USA TODAY (Apr.
23, 2014), http://www.usatoday.com/story/news/nation/2014/04/23/nih-budget
-cuts/8056113; Francis Collins Warns of ‘Devastating’ Effect of Budget Crisis
on NIH-Funded Research, GENOMEWEB (Oct. 7, 2015), https://www
.genomeweb.com/research-funding/francis-collins-warns-devastating-effect
-budget-crisis-nih-funded-research.
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funding shortages have the immediate effect of denying innovative research projects. The National Institutes of Health (NIH)
was once able to fund one in three research proposals, but in
the past ten years, this funding ratio has dropped to one in
21
six. NIH’s budget has lost twenty-five percent of its purchas22
ing power over the last decade due to inflation. Limited funding also presents long-term problems of current researchers
23
leaving the field and fewer researchers coming into the field.
Studies have shown that scientists are considering moving
24
from the United States to other countries to do research.
Many commentators are concerned that continued shortages in
research funding will have lasting negative repercussions for
25
genetic and genomic research.
Several articles have focused on the ethical and legal issues surrounding the problem of incidental findings in genetics
26
and genomics research. This Note analyzes the cost implications of a duty to return incidental findings and how these cost
implications should shape future policy recommendations for
genetics and genomics research. This Note takes previous recommendations one step further to provide an ethically, legally,
21. Szabo, supra note 20; see also MacKenzie Elmer, Federal Budget Woes
Slow Medical Research, DES MOINES REG. (Sept. 29, 2014), http://www
.desmoinesregister.com/story/news/education/2014/09/29/federal-budget-woes
-slow-medical-research/16411759.
22. Szabo, supra note 20; see also Editorial, Elizabeth Warren Plan Would
Bolster NIH Funding, BOS. GLOBE (Mar. 6, 2015), http://www.bostonglobe
.com/opinion/editorials/2015/03/05/elizabeth-warren-plan-would-bolster-nih
-funding/rlFDSwUz5zhNjXklIPCPWN/story.html.
23. Szabo, supra note 20; see also John LaMattina, The NIH Needs More
Funding—Here’s a Proposal That Can Help, FORBES (Mar. 5, 2015), http://
www.forbes.com/sites/johnlamattina/2015/03/05/the-nih-needs-more-funding
-heres-a-proposal-that-can-help; Claire Pomeroy & Eric. R. Kandel, Opinion,
Cutting Budgets for Medical Research Is Dangerous, CNN (June 6, 2014),
http://www.cnn.com/2014/06/06/opinion/pomeroy-kandel-medical-research.
24. Szabo, supra note 20.
25. See, e.g., id.; Pomeroy & Kandel, supra note 23.
26. See L. Black et al., Funding Considerations for the Disclosure of Genetic Incidental Findings in Biobank Research, 84 CLINICAL GENETICS 397, 397
(2013) (“Much of the detail about how [incidental findings] should be handled
comes from scientific and ethics literature.”). See generally Stephanie A.
Alessi, The Return of Results in Genetic Testing: Who Owes What to Whom,
When, and Why?, 64 HASTINGS L.J. 1697 (2013) (addressing the ethical foundations for a duty to return incidental findings and the potential sources of
legal duties); Richard L. Furman, Jr., Genetic Test Results and the Duty To
Disclose: Can Medical Researchers Control Liability?, 23 SEATTLE U. L. REV.
391 (1999) (analyzing potential legal liability to researchers under claims in
tort, contract, and property law); Pike et al., supra note 12 (proposing that researchers’ potential legal liability should be addressed through the informed
consent process).
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and fiscally responsible default rule to apply when researchers
are not sure whether offering to return results is appropriate.
This Note proposes that researchers should default to offering
to return incidental findings in genomics or genetics research to
participants, unless the researchers weigh the costs and benefits of returning versus the costs and benefits of not returning
and reasonably conclude that they should not return the incidental findings. The default rule places a minimal burden on
researchers and also provides guidance and a sense of security
from the threat of future legal liability. Part I of this Note discusses the history of medical research liability and the debate
over the issue of returning research results and incidental findings. Part II analyzes the cost implications of current recommendations for researchers faced with incidental findings in
genetics and genomics research. Part III argues that policymakers need to take cost implications into account, proposes
some potential recommendations that would address these cost
considerations, and defines a default rule that will provide
guidance without overly burdening the genetics and genomics
research enterprise.
I. MEDICAL RESEARCHER LIABILITY AND THE DEBATE
OVER RETURN OF RESEARCH RESULTS AND
INCIDENTAL FINDINGS
27

Medical research has a long history in the United States.
Beginning in the 1960s, research institutions started to develop
guidelines to ensure the protection of human subjects in re28
search. Section A will briefly discuss the history of medical research and researcher liability. Section B will present the debate in genetics and genomics research over whether
researchers should offer results to participants. Finally, Section
C will introduce some of the cost implications of returning research results to participants.
A. HISTORY OF MEDICAL RESEARCH AND RESEARCHER
LIABILITY
The goal of medical research is to “pursue generalizable
27. For a general overview of the medical and research history in the
United States, visit History of Medicine, NAT’L INSTITS. HEALTH, http://
www.nlm.nih.gov/hmd (last updated Oct. 21, 2015).
28. Amy L. Davis & Elisa A. Hurley, Setting the Stage: The Past and Present of Human Subjects Research Regulations, in BASIC BIOETHICS: HUMAN
SUBJECTS RESEARCH REGULATION: PERSPECTIVES ON THE FUTURE 9, 9–11 (I.
Glenn Cohen & Holly Fernandez Lynch eds., 2014).
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29

knowledge that will benefit society.” On its face, medical research does not explicitly create a duty between the researcher
30
and the participant. Unlike physician-patient relationships,
researcher-participant relationships are not considered fiduci31
ary relationships, which is a relationship held in trust. Thus,
researchers are not required to act “primarily for the benefit of
32
the individual research subject.”
The rights and wellbeing of research participants, however,
33
are not inconsequential. The “Common Rule” and FDA regula34
tions govern human subjects research. The “Common Rule,”
also known as the Federal Policy for the Protection of Human
Subjects, applies to nearly all federally-funded human subjects
35
research. As a part of obtaining “legally effective informed
36
consent of the subject,” the Common Rule requires that researchers disclose reasonably foreseeable risks and benefits to
29. Ulrich, supra note 18, at 128.
30. This lack of a duty is in stark contrast to physicians who are “regarded as fiduciaries of their patients and as such are expected to act in their patients’ best interests.” Roger L. Jansson, Researcher Liability for Negligence in
Human Subject Research: Informed Consent and Researcher Malpractice Actions, 78 WASH. L. REV. 229, 242 (2003) (footnotes omitted).
31. See Franklin G. Miller et al., Incidental Findings in Human Subjects
Research: What Do Investigators Owe Research Participants?, 36 J.L. MED. &
ETHICS 271, 273 (2008) (“Unlike the physician, the investigator has not undertaken to act in the subject’s best interests when entering into the relationship;
she has not taken on a fiduciary role.”).
32. McGuire et al., supra note 11, at 721; see also Wolf, Role of Law, supra
note 11, at 443 (“Both law and ethics have conceived of the research and clinical spheres as generally quite distinct.”).
33. 45 C.F.R. § 46 (2014). In September 2015, the Department of Health
and Human Services announced proposed revisions to the Common Rule. See
Human Subjects Research Protections: Enhancing Protections for Research
Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 80
Fed. Reg. 53,931, 53,936 (proposed Sept. 8, 2015), https://www.federalregister
.gov/articles/2015/09/08/2015-21756/federal-policy-for-the-protection-of
-human-subjects. The proposed rule revision seeks to make the informed consent process more meaningful. Id.
34. 21 C.F.R. §§ 50, 56 (2015). These regulations apply to research involving experimental drugs, biological products, and medical devices subject to
FDA approval. Id. Similar to the Common Rule, the FDA regulations require
informed consent and IRB review and approval. Id. §§ 50.20–50.27; id.
§§ 56.103, 56.109, 56.111. Unlike the Common Rule, the FDA regulations provide fewer exceptions to the informed consent requirements and fewer waivers. Compare 45 C.F.R. § 46.116(c)–(d) (2014) (delineating the Common Rule’s
requirements for modifying or waiving consent), with 21 C.F.R. § 50.23 (2015)
(listing FDA regulations’ exceptions from general consent requirements).
35. See Federal Policy for the Protection of Human Subjects (“Common
Rule”), U.S. DEP’T HEALTH & HUMAN SERVS., http://www.hhs.gov/ohrp/
humansubjects/commonrule/index.html (last visited Nov. 30, 2015).
36. 45 C.F.R. § 46.116.
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37

participants. The Common Rule also directs researchers to
minimize potential risks to participants and ensure that the
38
risks are reasonable in relation to the anticipated benefits.
The Common Rule, however, does not create an express cause
39
of action for participants who allege a violation.
Although the Common Rule does not enable participants to
sue researchers, research participants may be able to recover
40
against researchers under a negligence regime. While lawsuits against researchers have been historically rare, research41
related litigation has been increasing. Several cases illustrate
the recent shift in courts’ treatment of researcher-participant
relationships and how these relationships may give rise to duties never before anticipated.
42
In Grimes v. Kennedy Krieger Institute, the Maryland
Court of Appeals held that “the very nature of nontherapeutic
research on human subjects can, and normally will, create spe43
cial relationships out of which duties arise.” Grimes involved
research on lead-paint abatement in houses rented to families
44
with young children. The researchers found that the plaintiffs’
45
children had elevated levels of lead in their blood. Plaintiffs
brought suit arguing that the researchers failed to warn them
46
of the hazardous levels of lead paint. Vacating the lower
47
court’s decision, the court of appeals found that the researchers had a duty given the researchers’ ability to “anticipate, discover, and understand the potential risks to the health of their
48
subjects.”
A few years before Grimes, the United States District
Court for the Northern District of Illinois found in Blaz v. Michael Reese Hospital that a physician leading a research program had a duty to warn a patient, whom the physician had
37. Id.
38. Id. § 46.111.
39. See Susan M. Wolf et al., The Law of Incidental Findings in Human
Subjects Research: Establishing Researchers’ Duties, 36 J.L. MED. & ETHICS
361, 368 (2008) [hereinafter Wolf et al., Law of Incidental Findings].
40. See Jansson, supra note 30, at 236.
41. See Michelle M. Mello et al., The Rise of Litigation in Human Subjects
Research, 139 ANNALS INTERNAL MED. 40, 40 (2003).
42. 782 A.2d 807 (Md. 2001).
43. Id. at 834–35.
44. Id. at 819.
45. Id. at 825.
46. Id. at 825–26.
47. Id. at 858.
48. Id. at 851.
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never treated, of the risks of previous treatment received. In
Blaz, the plaintiff participated in a research study performed
by the defendant, a physician who had never treated the plain50
tiff. The study analyzed the connection between x-ray treatments, which the plaintiff had undergone as a child, and the
51
prevalence of tumors. Almost 20 years after the study, the
plaintiff developed neural tumors and sued the physician for
failure to warn him of the study’s finding that he might be at
52
an increased risk for developing tumors. Even though the defendant did not have a physician-patient relationship with the
plaintiff, the district court found that the defendant owed a duty to the plaintiff because of the reasonable foreseeability of
harm, the negligible burden on the defendant to warn, the de53
fendant’s “special position to acquire the information” and the
54
plaintiff “was in no position to find out” the information. Like
Grimes, the court in Blaz also found that the defendant’s position as the head of the research program created a “special relationship” required “for a finding of duty in the absence of a
55
physician-patient relationship.”
Some commentators argue that cases like Grimes and Blaz
represent a larger trend of increased liability exposure for medical researchers and that these cases could lead to more law56
suits in the future. While the legal duty of researchers remains unclear and scarcely addressed in courts, the issue of
returning research results and incidental findings presents
some interesting challenges that the court will likely have to
face someday in the near future.
B. DEBATE OVER RETURN OF RESEARCH RESULTS AND
INCIDENTAL FINDINGS
The use of genetics and genomics for nontherapeutic re57
search raises challenging ethical and legal issues for re49. 74 F. Supp. 2d 803, 805 (N.D. Ill. 1999).
50. Id. at 804.
51. Id.
52. Id.
53. Id. at 805–06.
54. Id.
55. Id. at 806–07.
56. See, e.g., Jansson, supra note 30, at 230 (“This period of increased legal and public scrutiny of the research enterprise will likely lead to a dramatic
rise in lawsuits by human subjects.”).
57. It is important to note a distinction between therapeutic research,
which has a possibility for immediate benefit to the research participants, and
nontherapeutic research, which does not offer immediate clinical benefits to
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searchers. During the course of genetics and genomics research,
researchers are likely to discover incidental findings. While in58
cidental findings can arise in any area of medical research,
genetics and genomics research raises particular concerns because of the likelihood and scope of potential incidental find59
60
ings. Some of these findings have clear clinical significance,
61
whereas other incidental findings have no clear significance.
Currently, researchers and others in the field are reaching
62
a general consensus that certain ethical obligations require
63
the return of incidental findings in some circumstances. It is
important to note that the ethical duty to return incidental
findings is distinct from the issue of legal obligations to return
64
incidental findings. Potential legal liability and the sources for
liability for failure to return incidental findings remains a point
65
of contention. Neither the Common Rule nor the FDA regula66
tions directly address incidental findings. Although no court
the participants. See Matthew P. Gordon, A Legal Duty To Disclose Individual
Research Findings to Research Subjects?, 64 FOOD & DRUG L.J. 225, 227
(2009).
58. See, e.g., id. at 224–26 (discussing incidental findings in MRI research
and CT colonography).
59. Pike et al., supra note 12, at 800.
60. See, e.g., Naomi H. Brodersen et al., Anticipated Reactions to Genetic
Testing for Hereditary Non-Polyposis Colorectal Cancer Susceptibility, 66
CLINICAL GENETICS 437, 437 (2004) (explaining that hereditary non-polyposis
colorectal cancer disorder “has been shown to be caused by mutations of DNA
mismatch repair genes”).
61. See, e.g., Catherine Gliwa & Benjamin E. Berkman, Do Researchers
Have an Obligation To Actively Look for Genetic Incidental Findings?, 13 AM.
J. BIOETHICS 32, 36 (2013) (“Genomic science is still in its infancy, and the
amount we know about the relationship between genomic data and human
disease is dwarfed by the amount we do not yet know.”).
62. See Ulrich, supra note 18, at 136–43 (grounding an ethical obligation
to return incidental findings in respect for the participants, beneficence, reciprocity, and other ethical principles). But see Leslie A. Meltzer, Undesirable
Implications of Disclosing Individual Genetic Results to Research Participants,
6 AM. J. BIOETHICS 28, 28 (2006) (“[T]heir justification for disclosure rests on
the mistaken view that principles of beneficence, respect, reciprocity, and/or
justice ethically require researchers to offer participants individual genetic
results.”).
63. See Clayton & McGuire, supra note 14 (“There is substantial consensus that people should be offered results that could trigger interventions that
are lifesaving or that could avert serious adverse health outcomes . . . .”).
64. Wolf, Role of Law, supra note 11, at 440–41.
65. See Pike et al., supra note 12, at 830; Wolf et al., Law of Incidental
Findings, supra note 39, at 362 (discussing the uncertainty of whether and
when a researcher may be liable for failing to return incidental findings).
66. For a discussion of how several provisions of the federal regulations
governing human subjects research are relevant to the disclosing and managing of incidental findings, see Wolf et al., Law of Incidental Findings, supra
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has directly addressed the issue of a researcher’s legal duty to
disclose incidental findings, increased researcher liability
claims and recent court cases create fear of legal liability for
genetics and genomics researchers.
While Grimes and Blaz suggest that researchers have some
sort of a special duty to their participants, only one case arguably addresses the issue of whether a researcher has a duty to
disclose individual research findings. In Ande v. Rock, the
plaintiffs sued researchers for failing to inform them that their
67
child had cystic fibrosis. The plaintiffs had their first child in
1993 and at that time, the plaintiffs received a pamphlet de68
scribing the cystic fibrosis research. The plaintiffs’ child was
placed in the “blinded control” group, which meant that although the plaintiffs’ child tested positive for factors indicative
69
of cystic fibrosis, the researchers did not inform the plaintiffs.
Two years later, the child was diagnosed with cystic fibrosis
and the plaintiffs had already conceived a second child, who
70
was also diagnosed with cystic fibrosis. The court ultimately
dismissed the plaintiffs’ medical malpractice and negligence
71
claims. For the medical malpractice claim, the court found
that no physician-patient relationship existed between the
plaintiffs and any of the defendants, so the medical malpractice
72
claim could not prevail. On the claim of negligence, the lower
court found that the claim was time-barred and plaintiffs did
73
not appeal the ruling.
Although the court never reached the issue of the researchers’ duty to return individual research results to the
plaintiffs, some legal scholars argue that Ande is still informa74
tive. Ande may reflect courts’ resistance to requiring re75
searchers to disclose individual research results. The lack of
litigation regarding return of research results and incidental
findings, however, has failed to calm fears of legal liability in
76
the research community.
note 39, at 366–68.
67. 647 N.W.2d 265, 268 (Wis. Ct. App. 2002).
68. Id. at 269.
69. Id.
70. Id. at 270.
71. Id. at 276; id. at 268 (“The circuit court dismissed all of the state
claims, except those for medical malpractice.”).
72. Id. at 272.
73. Id. at 269.
74. See, e.g., Gordon, supra note 57, at 234.
75. See id.
76. See Wolf, Role of Law, supra note 11, at 437 (“It appears to be little
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In addition to the previous litigation involving researchers
and courts expanding the duties of researchers, ethical obligations may create unintended consequences that burden the research enterprise and put researchers in the firing line for neg77
ligence lawsuits. Several articles have addressed the fear that
ethic recommendations will be misconstrued as legal obliga78
tions. As researchers adopt these ethical recommendations,
these new practices may give rise to a corresponding legal
79
standard of care for researchers. Two scholars, Ellen Wright
Clayton and Amy McGuire, stated “One thing is certain—if
these practices become routine, they will be legally required.
80
This is the way tort law has worked for decades.”
Besides the concerns of ethical obligations morphing into
legal obligations, the current ethical recommendations provide
inconclusive guidance for researchers, leading to inconsistent
81
practice. Although many commentators and researchers agree
that “[incidental findings] should be returned only when they
are analytically valid, have significant health implications, and
82
are clinically actionable,” these criteria fail to provide all the
83
answers. Inconsistent practice arguably can lead to legal liareassurance that no court . . . has yet found anyone liable for mishandling return of results or incidental findings in the context of human subjects research.”).
77. See, e.g., W. Nicholson Price II, Legal Implications of an Ethical Duty
To Search for Genetic Incidental Findings, 13 AM. J. BIOETHICS 48, 48 (2013)
(explaining that ethical obligations may create a standard of care and “provide
grounds for a negligence lawsuit”).
78. See, e.g., Wolf, Role of Law, supra note 11, at 438 (“Though law and
ethics are sometimes confused, they are distinct.”).
79. See Clayton & McGuire, supra note 14, at 475 (discussing how ethical
obligations may become evidence of standard of care for researchers); Pike et
al., supra note 12, at 815 (“[A]s this emerging ethical obligation increasingly
becomes standard or customary practice in research, the emerging ethical obligation could give rise to a legal obligation to return [incidental findings], the
failure of which could result in legal liability.”); Price, supra note 77, (“[I]f an
ethical duty to search for incidental genetic findings arises and becomes widespread at some point in the future, it may become the legal standard of
care . . . .”).
80. Clayton & McGuire, supra note 14, at 475.
81. See Pike et al., supra note 12, at 808–09.
82. Id. at 809.
83. See Gordon, supra note 57, at 253 (“[T]he determination whether a
particular individual research finding has clinical utility may often be far from
simple . . . . In addition, the investigators may not be adequately trained to
assess clinical utility.”); Robert Klitzman, Questions, Complexities, and Limitations in Disclosing Individual Genetic Results, 6 AM. J. BIOETHICS 34, 35
(2006) (“[D]efinitional questions will arise about results that are neither clearly ‘analytically valid’ nor invalid, but of indeterminate validity. Results may
range significantly in the precise degree to which they identify a characteris-
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bility for both ends of the spectrum—the return of incidental
84
findings or the failure to return incidental findings.
Requiring researchers to return incidental findings to participants also raises serious concerns about therapeutic miscon85
ception. Although a consistent definition has not been estab86
lished, therapeutic misconception occurs “when a research
subject fails to appreciate the distinction between the imperatives of clinical research and of ordinary treatment, and therefore inaccurately attributes therapeutic intent to research pro87
cedures.” In the case of genetics and genomics research,
returning certain incidental findings, especially those with ambiguous or unknown significance, arguably causes “unnecessary
scares” and violates the ethical obligation to minimize harm to
88
research participants. The risk for therapeutic misconception
makes the need for legal clarity especially important for genet89
ics and genomics researchers. More research is needed to see
whether and to what extent return of results creates a therapeutic misconception, but the concern should be considered
when addressing the ethical and legal obligations of genetic
90
and genomic researchers.
tic—that is, their predictive value.”).
84. See Pike et al., supra note 12, at 812–13 (“This gap between the
emerging majority view that some [incidental findings] ought to be returned
and the reality that [incidental findings] often are not returned . . . has led to
growing concern about potential legal liability . . . . [T]here is a growing sense
that we may be standing at the precipice of legal liability . . . .”); cf. Gary E.
Marchant & Rachel A. Lindor, Personalized Medicine and Genetic Malpractice,
15 GENETICS MED. 921, 921 (2013) (“[W]hen a new technology such as genetic
testing is taken up . . . unevenly, a gap develops between the care provided by
early adopters versus that by late adopters, again providing an opening for liability based on the disparity in treatment, with both early adopters and late
adopters facing potential risk for being too quick or not quick enough to adopt
the new technology.”).
85. See Clayton & McGuire, supra note 14, at 474.
86. See Gail E. Henderson et al., Clinical Trials and Medical Care: Defining the Therapeutic Misconception, 4 PLOS MED. 1735, 1735 (2007).
87. Charles W. Lidz & Paul S. Appelbaum, The Therapeutic Misconception: Problems and Solutions, 40 MED. CARE 55, 57 (2002).
88. Ellen W. Clayton & Lainie F. Ross, Letter to the Editor, Implications
of Disclosing Individual Results of Clinical Research, 295 J. AM. MED. ASS’N
37, 37 (2006).
89. See Alessi, supra note 26, at 1712–13 (“[A]n individual subject might
misinterpret the goal of the research and where the project’s priorities lie—
that is, in the population rather than the individual. The potential for misunderstanding makes it imperative that any legal duty to report results be narrowly drawn so as not to place a burden on researchers that will only undermine the research it aims to promote.”).
90. See Clayton & McGuire, supra note 14, at 474 (explaining that the issue of therapeutic misconception “deserves further study”).
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C. RETURN OF INCIDENTAL FINDINGS AND COST
CONSIDERATIONS
The ethical and legal ambiguity surrounding return of incidental findings raises several cost concerns for genetics and
91
genomics researchers. Numerous commentators have expressed anxiety that a legal duty to return incidental findings
or individual research results will overly burden the research
enterprise and threaten the ultimate purpose of medical re92
search. The potential cost implications of a duty to return incidental findings to research participants can be significant and
93
requires more consideration.
One significant cost of returning incidental findings is the
cost of assuring that the results are analytically valid, clinically
valid, and actionable. It is clear that disclosing incidental find94
ings imposes costs on the research enterprise. Prior to disclosing incidental findings to participants, researchers must verify
and evaluate the findings to prevent disclosure of mistaken or
misleading data, which would harm the participant by causing
95
undue anxiety and unnecessary testing. The costs—including
time, money, and resources—of determining the validity and
significance of the results, confirming these results, and providing adequate follow up and counseling can be extremely bur-

91. See generally Conrad V. Fernandez et al., Considerations and Costs of
Disclosing Study Findings to Research Participants, 170 CAN. MED. ASS’N J.
1417, 1417 (2004) (discussing the costs of disclosure as three broad categories:
risk associated with the procedures, consequences of disclosure, and logistics
of the study); Kathryn A. Phillips et al., Is the “$1000 Genome” Really $1000?
Understanding the Full Benefits and Costs of Genomic Sequencing, 23 TECH. &
HEALTH CARE 373 (2015).
92. See Miller et al., supra note 31, at 278 (“As a general principle, the
scope of the responsibility for incidental findings should be assessed in light of
the potential impact on the primary mission of research, which is to promote
socially valuable, generalizable knowledge.”); Pilar N. Ossorio, Letting the
Gene Out of the Bottle: A Comment on Returning Individual Research Results
to Participants, 6 AM. J. BIOETHICS 24, 25 (2006) (“If offering individual results becomes the norm, I fear that we will sacrifice a tremendous amount of
research . . . .”); cf. Bledsoe et al., supra note 9, at 104 (arguing that in the context of biobanks, “the costs and burdens to the research enterprise more broadly could be enormous and one cost to society could be inhibiting important research”).
93. See Parens et al., supra note 8 (“Our approaches have to take into account the real costs associated with generating and reporting such information
. . . .”); Wolf et al., Law of Incidental Findings, supra note 39, at 364–65
(“Striking the right balance between necessary management of [incidental
findings] and containment of research costs will be important.”).
94. See Pike et al., supra note 12, at 802.
95. See Wolf et al., Law of Incidental Findings, supra note 39, at 376.
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96

densome on the research enterprise.
Disclosing incidental findings may also impose significant
costs by requiring researchers to obtain meaningful informed
consent. Researchers are required to obtain informed consent
97
from research participants. If researchers are required to return or at least offer to return incidental findings, this could
drastically change the process of receiving informed consent.
Researchers will likely struggle to provide participants enough
information to allow participants to give meaningful informed
98
consent. Some commentators fear that the cost of acquiring
consent and returning incidental findings could “hobble . . . crit99
ical areas of research.” Obtaining informed consent could pre100
sent a significant cost for researchers who face a duty to return incidental findings and these costs should be considered
when determining researchers’ duties to participants.
Besides the cost of obtaining informed consent, the act of
101
returning the incidental results is difficult and costly. Genetics and genomics information is difficult to explain to participants and this task becomes even more difficult when the im102
plications of genetic information are unknown or unclear.
Sometimes, the researchers are not the most qualified to share
the incidental findings because they may lack the skill and
knowledge to convey the results in a meaningful and under96. See Pilar Ossorio, Taking Aims Seriously: Repository Research and
Limits on the Duty To Return Individual Research Findings, 14 GENETICS
MED. 461, 464 (2012) (“The burdens and costs of returning individual IFs and
RRs—including money, people’s time, and the opportunity cost of not doing
more research because one is engaged in returning information to contributors—aggregate swiftly.”). See generally Ulrich, supra note 18, at 132 (discussing the minimum requirements for returning results to participants).
97. 45 C.F.R. § 46.116 (2014). The National Human Genome Research Institute defines “informed consent” as “[a] voluntary agreement to participate
in human subjects research . . . based on adequate knowledge and understanding.” Informed Consent for Genomics Research: Glossary, NAT’L HUM. GENOME
RES. INST., https://www.genome.gov/27559022 (last visited Nov. 30, 2015).
98. See Beskow & Burke, supra note 7 (“[I]t is difficult to imagine how
participants could be given enough information to make a fully informed decision . . . .”).
99. Clayton & McGuire, supra note 14, at 475.
100. See, e.g., id. (explaining that the Centers for Disease Control and Prevention decided to forego genetic research as the “cost of obtaining adequate
consent was estimated to be in the millions of dollars”).
101. See Bledsoe et al., supra note 9 (“Delivering genetic information is
costly and complex.”).
102. See Clayton & McGuire, supra note 14, at 476 (“Helping people understand complex, probabilistic information is hard enough; it becomes much
more difficult when that information is new and its clinical impact is not
clear.”).

2016]

A RESPONSIBLE DEFAULT

1185

103

standable way to the participant. Researchers may need help
returning incidental findings and this may impose more costs
on researchers by requiring them to hire additional staff or
spend more time explaining these results.
As stated above, researchers facing an ethical obligation to
return incidental findings may face future legal liability if that
ethical obligation morphs into a legal obligation. Legal obliga104
tions will undoubtedly lead to increased costs for researchers.
Arguably, once a standard of care is established, the standard
105
is likely to persist. Furthermore, researchers may be motivated to continue to return incidental findings, as a form of “defensive research,” analogous to the practice of defensive medi106
cine by physicians. The mere threat of liability may drive
researchers’ behavior and impose additional burdens on the re107
search enterprise.
While many commentators discuss the costs that researchers may face when returning incidental findings, some commentators also discuss the potential implications for the health
care system. Clayton and McGuire referred to this as the
108
“largely unspoken concern.” Drawing a parallel to the clinical
context, Clayton and McGuire argue that returning incidental
findings may increase health care costs, both for the individual
and society at large, because these findings will potentially lead
109
to downstream tests and side effects. Clayton and McGuire
provide a helpful example of variants in HFE, the gene associ110
ated with hemochromatosis. Arguably, these results of variants should not be shared when uncovered in research because
population-based screening for the same variants was rejected
as not cost effective because the variants were poorly pene-

103. See Sharon F. Terry, The Tension Between Policy and Practice in Returning Research Results and Incidental Findings in Genomic Biobank Research, 13 MINN. J.L. SCI. & TECH. 691, 721–22 (2012).
104. See Ulrich, supra note 18, at 134 (arguing that “potential downstream
cost of researcher liability could evolve from creating an ethical duty”).
105. See Price, supra note 77 (explaining that once a legal duty is established, the duty will continue in the long term “because the legal standard of
care is generally a one-way ratchet to which requirements may be added but
only rarely removed”).
106. Id. at 49.
107. See Wolf et al., Law of Incidental Findings, supra note 39, at 366 (emphasizing that the “fear of legal liability should not drive the evolution of duties”).
108. Clayton & McGuire, supra note 14, at 475.
109. Id.; see also Terry, supra note 103, at 721.
110. Clayton & McGuire, supra note 14, at 475.
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111

trant.
While returning results imposes costs, not returning results can also be costly. Most literature fails to address this aspect of cost to return, but the tangible and intangible costs of
not returning incidental findings to participants can be detrimental to society as well as the research enterprise. First, not
returning incidental findings can be harmful to society through
increased demands on the health care system. If a researcher
returns an incidental finding to a participant, this individual
may be able to take preventative steps to avoid future health
care costs. Thus, by not returning their findings, researchers
may deprive participants of the opportunity to take these steps
112
and avoid increased health care costs in the future. Second,
not returning results can lead to intangible costs that are difficult to quantify, but could threaten the public perception of genomics and genetics research. Society’s loss of trust and the
113
perceived lack of reciprocity could lead individuals to forego
participating in genomics and genetics research. Although these costs are difficult to calculate, these negative implications
should also be considered when determining whether incidental
findings should be offered to participants.
114
Given the extent and scope of these potential costs, plus
recent budget concerns, the legal ambiguity surrounding researchers’ duty to return incidental findings to participants
115
presents compounding problems for researchers. The goal of
111. Id.
112. The cost-effectiveness of preventative care raises its own debates and
criticisms that go beyond the scope of this Note. See generally Joshua T. Cohen
et al., Does Preventative Care Save Money? Health Economics and the Presidential Candidates, 358 NEW ENG. J. MED. 661, 661 (2008) (“Studies have concluded that preventing illness can in some cases save money but in other cases
can add to health care costs.”).
113. See Jennifer Viberg et al., Incidental Findings: The Time Is Not Yet
Ripe for a Policy for Biobanks, 22 EUR. J. HUM. GENETICS 437, 438 (2014)
(“[Reciprocity] holds that people deserve something in return for their contribution . . . . It may also be argued that research would benefit from disclosing
individual research results to participants; because offering something in return might motivate participation . . . [and] could be useful in recruiting and
retaining research participants.” (citations omitted)).
114. Calculating these costs presents a significant hurdle that further research will need to address. See Terry, supra note 103, at 720 (“In a climate of
evolving technology, data aggregation, and societal interest in genetic information, it is difficult to determine the weight of benefits and risks.”); Susan M.
Wolf, Letter to the Editor, Return of Results in Genomic Biobank Research:
Ethics Matters, 15 GENETICS MED. 157, 158 (2013) (“Quantifying the cost of
handling [individual research results] and [incidental findings] will not be
easy.”).
115. See, e.g., Beskow & Burke, supra note 7, at 4 (“In some contexts, the
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medical research is to benefit society as a whole, rather than
the individual participants, so the costs imposed on the research enterprise should be included in the calculus to determine and clarify the ethical and legal obligations of researchers
to return incidental findings.
II. ANALYZING POTENTIAL COSTS OF RETURNING
INCIDENTAL FINDINGS
A duty to disclose incidental findings, whether ethical or
legal, is costly. Returning those findings is costly. The reality is
that medical researchers are faced with tradeoffs. Researchers
have limited funding and scarce resources. These scarce resources need to be allocated efficiently in order to advance the
goal of medical research, which is the pursuit of generalizable
knowledge that benefits society as a whole. Returning incidental findings has the ultimate effect of diverting money,
time, and researchers away from actual research. This Note
does not argue that incidental findings should never be returned to participants, but it does strive to point out the need
for research, discussion, and consideration of the cost implications of returning incidental findings in genetics and genomics
research. Section A addresses what incidental findings should
be offered to participants. Section B discusses who should offer
to return the results. Section C analyzes who should pay to return incidental findings, while Section D looks at how long a
potential duty to return findings could last. Finally, Section E
summarizes the potential costs of not returning incidental findings to research participants.
A. WHAT SHOULD BE RETURNED?
A good starting point for this analysis is looking at what
findings should be returned, which is not an easy question to
answer. The question encompasses several other issues, including informed consent, verification of the results, the scope of
the results that should be returned, and the scope of a researcher’s duty to search for incidental findings buried in their
results. This Note will address each of these issues in turn.
The most recent recommendations for returning incidental
findings were published in 2014 by the Clinical Sequencing Exrationale for providing individual results is insufficient to justify spending
scarce research resources to do so.”); Klitzman, supra note 83 (“[R]esearch resources are already limited, given budgetary constraints at the National Institutes of Health . . . yet the costs of testing and counseling can be very high.”).
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ploratory Research (CSER) Consortium and the Electronic
Medical Records and Genomics (eMERGE) Network working
116
group. The working group delineated a floor and a ceiling for
117
returning research results. The working group also set forth
five guiding principles and discussed remaining areas of con118
troversy. Using these recommendations as a starting point,
this Section will address remaining questions related to obtaining informed consent, verifying the validity of results, determining the scope of results that should be returned, and addressing the duty to search.
1. Informed Consent
The issue of what to return to research participants starts
with consent. In other words, what has the participant said
about his or her desire to receive potential incidental findings.
The Common Rule requires that researchers obtain “legally ef119
fective informed consent” from the research participant. The
need for informed consent and what constitutes informed consent has generated considerable debate, some of which goes beyond the scope of this Note, in the genetics and genomics research community.
Consent is very much relevant to the potential costs im120
posed on researchers. For genetics or genomics research, genetic counselors are needed to provide the necessary information to allow participants to give adequate informed
121
consent. The role of genetic counseling is to help people understand the medical and psychological implications of genetic
122
and genomic contributions to disease. Because of their short
116. Jarvik et al., supra note 18.
117. Id. at 821 (defining the floor “as the return of well-established, important actionable genetic findings relevant to the intent of the research study
or uncovered in the course of usual research procedures” and the ceiling “as
the entire genome sequence or some representation of it”).
118. Id.
119. 45 C.F.R. § 46.116 (2014).
120. See Clayton & McGuire, supra note 14, at 475 (providing an example
of one study in which attaining adequate consent would cost millions of dollars).
121. See Ulrich, supra note 18, at 132. But see Paul S. Appelbaum et al.,
Models of Consent to Return of Incidental Findings in Genomic Research 44,
HASTINGS CTR. REP. 22, 24, 27 (2014) (outlining four different models of consent to return of incidental findings and concluding that “[n]one of the possible
models for informed consent to return of incidental findings in genomic research is ideal”).
122. Barbara Bernhardt, Genetic Counselors and the Future of Clinical Genomics, 6 GENOME MED. 49, 49 (2014). Helping participants understand potential implications of genomic sequencing is a complicated process that re-
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123

supply, genetic counselors are usually quite expensive. In addition to genetic counselors, most commentators agree that
consent forms should address the possibility of incidental find124
ings. Besides the ethical and legal justifications for providing
this information, the cost of reconsent provides additional support for consent prior to the start of the research study.
Reconsent is the process of recontacting the participant to re125
ceive their consent for additional use of their information or
the potential return of results that had not been addressed in
126
the prior consent process. Two recent studies have calculated
the average cost of reconsent to be approximately $50 per indi127
vidual. These costs are likely to vary depending on the method of reconsent.
Related to the issues of consent and reconsent, many ethicists argue that a person has a right not to know one’s own

quires tempering participants’ expectations, educating participants about the
limitations of genomic sequencing and genetic testing, and explaining the uncertainty of some potential results. Id. at 50. A recent study interviewed twenty-nine genetic counselors and research coordinators about their experiences
with obtaining informed consent for genomic sequencing, highlighting the
challenges with participant understanding and managing participant expectations. Ashley N. Tomlinson et al., “Not Tied up Neatly with a Bow”: Professionals’ Challenging Cases in Informed Consent for Genomic Sequencing, J.
GENETIC COUNSELING (forthcoming 2016) (“He had highlighted the consent
form very carefully and he highlighted the word ‘genome’ and he kept saying
‘gnome’ . . . he was like ‘What’s a gnome? What does that mean? . . . Is that in
my body? Can you take it out of me?’”).
123. See Klitzman, supra note 83 (“Genetic counselors are already in short
supply.”); Ulrich, supra note 18, at 133.
124. See Wolf et al., Law of Incidental Findings, supra note 39, at 374 (arguing that a process must be in place to review the informed consent plan to
ensure that potential participants are aware of the possibility of incidental
findings and whether and when this information will be offered); Wolf et al.,
Managing Incidental Findings, supra note 8, at 228.
125. Michele L. Cote et al., Re-contacting Participants for Inclusion in the
Database of Genotypes and Phenotypes (dbGaP): Findings from Three CaseControl Studies of Lung Cancer, 6 GENOME MED. 54, 54 (2014).
126. See Paul S. Appelbaum et al., Researchers’ Views on Informed Consent
for Return of Secondary Results in Genomic Research, 17 GENETICS MED. 644,
645 (2014) (describing a staged consent process in which there is a “brief mention of secondary findings at the time of initial consent but with more detailed
consent for return of specific findings obtained if and when reportable results
are found”).
127. Cote et al., supra note 125, at 57 (estimating the total cost of reconsent to be the annual salary of one full-time interviewer, which resulted in
approximately $47.60 per individual); Evette J. Ludman et al., Glad You
Asked: Participants’ Opinions of Re-Consent for dbGaP Data Submission, 5 J.
EMPIRICAL HUM. RES. ETHICS 9, 15 (2010) (finding that cost of seeking reconsent was approximately $50 per participant).
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128

genes or genomic sequence and if they do not consent to the
return of genetic and genomic research results or incidental
findings, then the researcher should not return anything. Indeed, one of the working group’s principles states that participants should have the right to refuse any results that are of129
fered. Thus, once a participant has denied consent to the
return of research results or incidental findings, the researcher
cannot offer to return any result to the participant.
2. Verifying the Analytical Validity of the Results
Another looming issue is whether the results must be veri130
fied in a CLIA-certified lab before being returned to the participant. As Gail P. Jarvik and her colleagues point out, this is
131
still an area of controversy. Before offering results to a participant, researchers must verify that their findings are analyti132
cally valid to prevent false reporting and potential harm to
participants. Some contend that this requires the results to be
133
tested in a CLIA-certified lab. Arguably, requiring results to
be CLIA certified would reduce the likelihood of returning inaccurate results. Inaccurate results could lead to unnecessary follow-up tests for the participant, increased costs for participants
and the health care system, and stress on the participant and
others. Most research labs, however, are not CLIA-certified
134
labs. Requiring CLIA certification could be costly to research135
ers. In some cases, CLIA certification of research results may
128. For more discussion on the debate over one’s right not to know in the
research context, see Gert Helgesson, Autonomy, the Right Not To Know, and
the Right To Know Personal Research Results: What Rights Are There, and
Who Should Decide About Exceptions?, 42 J.L. MED. & ETHICS 28 (2014).
129. Jarvik et al., supra note 18.
130. Clinical Laboratory Improvement Amendments (CLIA) is a federal
statute that dictates the certification and oversight of clinical laboratory testing. Certification of Laboratories, 42 U.S.C. § 263a (2012). A CLIA-certified lab
is a lab that is in compliance with the CLIA regulations.
131. Jarvik et al., supra note 18, at 822.
132. Lisa Eckstein et al., A Framework for Analyzing the Ethics of Disclosing Genetic Research Findings, 42 J.L. MED. ETHICS 190, 194 (2014) (“The accuracy of predictions about a genetic variant’s presence or absence in a research participant is at the heart of most definitions of analytic validity.”).
133. See, e.g., Vardit Ravitsky & Benjamin S. Wilfond, Disclosing Individual Genetic Results to Research Participants, 6 AM. J. BIOETHICS 8, 10 (2006).
134. Ellen Wright Clayton, Incidental Findings in Genetics Research Using
Archived DNA, 36 J.L. MED. & ETHICS 286, 290 (2008) (“Most research laboratories do not adhere to CLIA requirements . . . .”).
135. Black et al., supra note 26, at 403 (arguing that such confirmatory
testing “will inevitably increase the costs of IF disclosure”); Klitzman, supra
note 83 (“Repeated tests through Clinical Laboratory Improvement Amend-
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136

be impossible. Some argue that if the results cannot be CLIA
certified, then participants should be informed of this at the
time of return and should be recommended to have the results
137
verified by a CLIA-certified lab.
Even if the results cannot be verified by a CLIA-certified
lab, researchers still have a responsibility to confirm the ana138
lytical validity of the results. Whether researchers verify
their results through a CLIA-certified lab or by some other
139
means, researchers must bear some costs to ensure that findings offered to participants are accurate. This cost is unavoidable for researchers, who must prevent harm or undue stress on
research participants and comply with ethical and legal mandates.
3. Scope of Incidental Findings that Should Be Offered to
Participants
Assuming valid informed consent was given and the results are adequately confirmed, what information should be offered to a participant? At the extremes of the spectrum of incidental findings to offer, researchers could offer to return
nothing or offer to return everything. While returning nothing
may seem advantageous because it minimizes the cost and
burden of interpreting and returning incidental findings, most
researchers have rejected this approach as being ethically un140
supportable.
On the other end of the spectrum is the offer to return everything. Although some argue that this approach may be very
beneficial for the research community by affirming the value of
research participation and building trust in the research enter141
prise, this approach is likely to be overly costly and burdensome on researchers and some results may arguably violate the
Common Rule by harming participants with the return of re-

ments (CLIA)-certified labs can also be expensive.”).
136. Jarvik et al., supra note 18, at 823 (explaining that “research circumstances might make a CLIA-compliant test impossible”).
137. See Wolf et al., Managing Incidental Findings, supra note 8, at 231.
138. It is important to note that analytical validity is distinct from clinical
validity. See id.
139. For examples of other means to verify analytical validity, see Eckstein
et al., supra note 132.
140. See Pike et al., supra note 12, at 833.
141. See Laura M. Beskow et al., Offering Aggregate Results to Participants
in Genomic Research: Opportunities and Challenges, 14 GENETICS MED. 490,
491–92 (2012).
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142

sults that have unknown significance. Furthermore, this approach may blur the lines of clinical care and medical research
143
and could, thus, contribute to therapeutic misconception.
Rather than selecting one of the two extremes, Jarvik and
colleagues state that “analytically and clinically valid information that is of an important and actionable medical nature
and that is identified as part of the research process should be
144
Essentially, when reoffered to a research participant.”
searchers have a valid research result for which the participant
can take preventative measures to protect his or her health,
145
then researchers should offer this result to the participant.
This general principle breaks down, however, when policymak146
ers try to define “actionable.”
The definition of “actionable” varies by research study and
147
context. One clear example of this is in a research study for
children. Should the child or the child’s parents be offered re148
sults of adult-onset findings? Historically, the answer has
149
been no. Some commentators argue, however, that these find150
ings are actionable and should be returned.
The danger of an ambiguous definition of “actionable” leads
to liability concerns down the road. If researchers fear that
they will be sued for not returning an “actionable” result, then
they may choose to return everything or more than they should.
As seen above, returning too much information can lead to negative consequences and impose costs on researchers and participants.
Given the ambiguity of how to define “actionable,” it is dif142. Id. at 492–93; Pike et al., supra note 12, at 835.
143. Beskow et al., supra note 141, at 493.
144. Jarvik et al., supra note 18.
145. Id. at 821.
146. Id. (“The definition of what is actionable is a matter of judgment.”).
147. Richard R. Fabsitz et al., Ethical and Practical Guidelines for Reporting Genetic Research Results to Study Participants: Updated Guidelines from a
National Heart, Lung, and Blood Institute Working Group, 3 CIRCULATION
CARDIOVASCULAR GENETICS 574, 575–76 (2010) (“Actionable means that disclosure has the potential to lead to an improved health outcome . . . . Actionable may include surveillance and interventions to improve clinical course, such
as by delaying onset, leading to earlier diagnosis, increasing likelihood of less
burdensome disease, or expanding treatment options.”).
148. Jarvik et al., supra note 18, at 821.
149. Id.
150. See id.; cf. Robert C. Green, ACMG Recommendations for Reporting of
Incidental Findings in Clinical Exome and Genome Sequencing, 15 GENETICS
MED. 565, 568 (2013) (recommending that searching for and returning findings should not be limited by the age of the participant in the clinical setting).
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ficult for researchers to predict how many actionable incidental
findings they may recover. Several studies have looked into the
likelihood of identifying incidental findings. Lucy-Enid Ding
and colleagues published a study in 2014 looking at a screening
151
panel of 24 conditions. They found that approximately 2.7% of
152
screened individuals would have an incidental finding. Michael O. Dorschner and colleagues performed a study in 2013 to
153
determine the likelihood of identifying actionable findings.
Christopher A. Cassa and co-authors found a rate of 6.88% of
participants having an incidental finding that was recommend154
ed for disclosure. But, Yali Xue and colleagues reported 11%
155
of 179 screened individuals had an incidental finding. These
studies illustrate the challenge for researchers to predict the
156
potential number of actionable incidental findings. Without
being able to reasonably predict the number of actionable incidental findings, researchers will struggle to predict the costs to
return such results.
4. Costs Associated with a Potential Duty To Search
Finally, if researchers have a responsibility to return some
research results to participants, does this responsibility require
researchers to search for results buried in one’s genome? Jarvik
and colleagues recommend that research resources should be
primarily used for scientific discovery and, thus, researchers do
157
not have a duty to search for findings. Such a duty is likely to
158
be costly and overly burdensome for researchers.
151. Lucy-Enid Ding et al., The Impact of Reporting Incidental Findings
from Exome and Whole-Genome Sequencing: Predicted Frequencies Based on
Modeling, 17 GENETICS MED. 197, 197 (2015).
152. Id. at 198.
153. Michael O. Dorschner et al., Actionable, Pathogenic Incidental Findings in 1,000 Participants’ Exomes, 93 AM. J. HUMAN GENETICS 631, 631
(2013).
154. Christopher A. Cassa et al., Disclosing Pathogenic Genetic Variants to
Research Participants: Quantifying an Emerging Ethical Responsibility, 22
GENOME RES. 421, 423 (2012).
155. Yali Xue et al., Deleterious- and Disease-Allele Prevalence in Healthy
Individuals: Insights from Current Predictions, Mutation Databases, and Population-Scale Resequencing, 91 AM. J. HUM. GENETICS 1022, 1030 (2012).
156. See also Julia Karow, As Labs Start Returning Incidental Findings,
Weighing Variant Pathogenicity Remains Challenge, GENOME WEB (May 14,
2014), https://www.genomeweb.com/sequencing/labs-start-returning-incidental
-findings-weighing-variant-pathogenicity-remains (“The lack of clear criteria
for classifying variants as pathogenic likely leads to differences in incidental
findings rates between laboratories . . . .”).
157. Jarvik et al., supra note 18.
158. See Wolf et al., Law of Incidental Findings, supra note 39, at 376.
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In 2013, Catherine Gliwa and Benjamin E. Berkman eval159
uated the benefits and costs of a duty to search. Gliwa and
Berkman conclude that researchers have no duty to search, relying in part on the costs that would be imposed on research160
ers. Prior to any filtering, researchers would be faced with
approximately 80,000 variants per exome or 3 to 4 million vari161
ants of each genome for each participant. Next, researchers
would filter these results to leave only those variants that are
162
most likely to cause disease. Then, researchers must determine whether a specific variant is likely to cause disease, but
163
this is a tedious process that must be done manually. Considerable time, resources, and money are needed to perform such
an analysis.
In addition, many commentators and policymakers fear
164
that an ethical duty to search may evolve into a legal duty.
Given the costs and resources required to satisfy a duty to
search, the threat of legal liability for failure to search could
have the negative consequence of driving researchers out of doing research as the costs of research may not justify the benefits.
Issues about what incidental findings to offer to research
participants and the costs of offering these results are extremely complex and can have serious legal implications. Issues of informed consent, analytical validation, which results should be
returned, and potential duties to search illustrate the complexity of returning incidental findings to participants. These issues
and how they are resolved have significant consequences for
both researchers and participants and thus require careful consideration by policymakers and those drafting recommendations.
B. WHO SHOULD RETURN?
Who should return the results is another area that raises
cost and legality concerns. At first glance it may seem obvious
to have the researchers return the results. The researchers designed the study. The researchers recruited the participants.
159. Gliwa & Berkman, supra note 61, at 32.
160. Id. at 41.
161. Id. at 37; see Leslie G. Biesecker, Opportunities and Challenges for the
Integration of Massively Parallel Genomic Sequencing into Clinical Practice:
Lessons from the ClinSeq Project, 14 GENETICS MED. 393, 394 (2012).
162. Gliwa & Berkman, supra note 61, at 37.
163. Id.
164. See Price, supra note 77, at 49.
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The researchers performed the genetic tests or genomic sequencing. The researchers found the incidental finding. In
Grimes, the court held that researchers have a “special rela165
tionship” with their participants and this could be interpreted
to mean that researchers should be the ones to offer to return
results to participants. But it is important to remember that
the researchers discovered an incidental finding, something
they were not looking for. The researchers may have no
knowledge of the significance of a particular variant, how to interpret the variant, or what the variant might mean (if any166
thing). The method of returning results remains an area of
167
contention and in need of further research.
One method proposed is that the researcher bears the responsibility to return incidental findings to participants. Returning genomic or genetic results in an ethical manner requires time and resources. Explaining genomic and genetic test
168
results is very complex. If the results yield novel findings or
have unknown significance, returning and explaining these re169
sults becomes exponentially more difficult. The danger of misinterpretation or miscommunication is significant. The threat
of misinterpretation may not be enough to justify no return of
findings, but it highlights the challenge facing researchers who
have to explain these results to a participant. These challenges
increase the amount of time, resources, and money that need to
170
be diverted from other areas of the research budget. In a recent study, researchers determined that to disclose results to
research participants cost $68 and required 78 minutes on av171
erage. These calculations are likely to vary considerably de172
pending on the type of study.
If the researcher has the responsibility to return and explain the incidental findings, the researcher may need to hire

165. Grimes v. Kennedy Krieger Inst., 782 A.2d 807, 834–35 (Md. 2001).
166. See Black et al., supra note 26, at 401 (“Variance on who should disclose [incidental findings] persists, and there is no clear overlap or consensus
in the guidance.”); Jarvik et al., supra note 18 (“[S]ome investigative teams are
not qualified to interpret and/or return the results.”).
167. Jarvik et al., supra note 18, at 823.
168. See Clayton & McGuire, supra note 14, at 476.
169. Id.
170. See Black et al., supra note 26, at 402 (explaining that researchers
may not have the “required time to prepare for and perform the disclosure”).
171. Kurt D. Christensen et al., Disclosing Individual CDKN2A Research
Results to Melanoma Survivors: Interest, Impact, and Demands on Researchers, 20 CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 522, 522 (2011).
172. See id. at 527–28.
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additional personnel to do so. Because researchers may not be
the most qualified to return the results, additional genetic
counselors or the participant’s clinician may need to be involved in the disclosure. Even if the researcher is qualified to
return the results, the researcher may not have the time to return the results. Regardless of the reason, hiring additional
personnel will increase research costs.
Some also fear that requiring the researchers to return the
results will blur the lines between clinical and research and
174
could lead to therapeutic misconception. Returning results
can lead participants to believe that researchers will provide
certain results or all results. Therapeutic misconception can
lead to negative consequences as participants who expect to receive certain results, even if they were informed that they
would not receive such results, may feel betrayed or cheated
175
when they do not receive those results. This could lead to serious implications for medical research as individuals begin to
distrust the research enterprise or if participants feel they are
being mistreated or disrespected. The potential negative stigma
caused by therapeutic misconception is difficult to quantify into
tangible costs.
While no explicit statute or court case imposes legal liability on researchers to return results, the potential for future liability should cause policymakers to consider these possible
downstream consequences and consider the costs when proposing policy guidelines. Who returns the results is an important
consideration from an ethical, legal, cost, and efficiency standpoint.
C. WHO PAYS?
Returning incidental findings to research participants can
be a costly endeavor. Deciding who will bear these costs has
important implications. Some argue that these costs should be
176
included in the research budget. While this may seem like an
173. See id. at 528.
174. See Alessi, supra note 26, at 1712; cf. supra notes 85–90 and accompanying text.
175. See Alessi, supra note 26, at 1711–12.
176. See, e.g., Fernandez et al., supra note 91, at 1419 (“Researchers and
granting agencies should consider the offer to return results to research participants as a mandatory part of practice and adjust budgets and duration of
funding accordingly.”); Wolf et al., Managing Incidental Findings, supra note
8, at 237 (“The cost of compensating the consultant for [incidental findings]
verification and evaluation should be built into the research budget. . . . Agencies funding research should support this expense as a cost of performing re-
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easy solution, making researchers bear more costs could have a
significant impact on the research enterprise and future research projects.
First, given the complex issue of calculating the costs to return incidental findings, researchers will face a daunting challenge to predict the funding they will need to return results.
The cost to return incidental findings is likely to vary substantially depending on a number of factors, including the design of
177
the research study. Ambiguity over what needs to be returned and how these results should be returned adds to this
complexity. This likely adds costs as researchers try to determine what they must do to be ethically and legally compliant.
Assuming the current budget for medical research funding
remains the same, as research projects require more funding,
fewer projects will actually receive funding. Once again, society
must face a trade-off between fewer research projects that receive more funding and return more incidental findings or more
research projects that have less funding and return fewer findings.
Rising costs of medical research are especially alarming in
light of recent budgetary concerns. The National Institutes of
Health (NIH) funding ratio has been cut in half over the last
178
decade. While NIH and other granting agencies face less
funding and researchers face increased costs, the result could
be fewer genetics and genomics research projects being funded
and long-term problems, such as researchers leaving the field
or researchers moving away from genetics and genomics re179
search.
A recent study has found that Canadian participants would
be willing to pay on average $445 to receive certain incidental
180
findings from genomic sequencing. The study also found that
only 66% of participants would choose to receive these re181
sults. While this may provide evidence that some costs may
be shifted to the participants, the ethical or legal obligations of
search ethically.”).
177. See Fernandez et al., supra note 91 (listing three broad categories that
affect the complexity of returning results).
178. Szabo, supra note 20.
179. Id.; see also Pomeroy & Kandel, supra note 23.
180. Dean A. Regier et al., Societal Preferences for the Return of Incidental
Findings from Clinical Genomic Sequencing: A Discrete-Choice Experiment,
187 CAN. MED. ASSOC. J. 190, 195 (2015). These results were likely to have severe health consequences, but there was recommended effective medical
treatment. Id.
181. Id.
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requiring participants to pay for receiving incidental findings is
unclear.
The threat of legal liability adds to genetics and genomics
research concerns. Although no court has held a researcher liable for failure to return or improperly returning incidental findings, ethical recommendations can begin to evolve into legal
standards of care. Requiring researchers to foot the bill for the
cost to return and to face potential liability can have negative
consequences on the research enterprise.
D. HOW LONG DOES THIS RESPONSIBILITY TO RETURN
INCIDENTAL FINDINGS LAST?
If researchers have to return incidental findings to research participants, then researchers need to know how long
they bear this responsibility. Jarvik and colleagues recommend
that this responsibility last only during the period of funding to
182
researchers. They go on to say, however, that researchers
183
may offer disclosure after the funding period ends. Other
commentators agree with Jarvik and her co-authors and argue
that the responsibility to offer ends after the research project is
184
over; however, some do not explicitly limit the responsibility.
How long the responsibility lasts raises a question about
the researchers’ responsibility to recontact participants after
the research project ends. Many commentators argue that such
a duty would extend researchers’ responsibilities beyond the
responsibilities placed on clinicians. Clinicians are not required
to monitor their patients’ conditions continuously, but rather
they respond to specific symptoms and situations when their
185
patients come in for an appointment. It is unusual for a clini186
cian to recontact a patient based on new research. So, to require a researcher to recontact would push the duties of a re187
searcher beyond the duties that exist in clinical practice.
Recontacting previous research participants can be costly
188
and time-consuming. A 2011 study led by Kurt D. Christensen and colleagues attempted to recontact 39 participants to
disclose CDKN2A gene test results and implications for mela182. Jarvik et al., supra note 18, at 823.
183. Id.
184. See, e.g., Fabsitz et al., supra note 147, at 577.
185. Clayton & McGuire, supra note 14, at 475.
186. Id.
187. Id. at 476.
188. See, e.g., Deborah Levenson, Legal, Ethical Issues Loom over Topic of
Recontacting Patients, 167 AM. J. GENETICS vii, vii (2015).
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189

noma risk. Per recontact attempt, the preparation to disclose
190
the results cost $611 and required 40 minutes. However,
costs to recontact are likely to vary. In the 2011 study, the researchers attempting to recontact participants had access to
experts in clinical genetics, genetic counseling, and other
191
health experts. This allowed the team to make specific rec192
ommendations for potential follow-up. Christensen and colleagues note that “[r]esearchers lacking the same access to interdisciplinary expertise may need to seek institutional
193
partners,” which will likely add to the cost of recontact.
Issues of how long a researcher’s responsibility to return
results lasts and researchers’ potential responsibilities to recontact participants raise cost and resource concerns. On one
end of the spectrum, the researcher’s responsibility could cease
with the research study. On the other end, researchers may
have duties that extend beyond the funding period and beyond
those of clinicians. The issue of how long this responsibility extends is important for the legal issues it implicates. As ethical
recommendations are adopted and standards of care are created, legal standards are likely to begin evolving. Eventually, the
threat of liability and the costs of legal compliance may exceed
the benefits or feasibility of performing genetics or genomics
research, ethically and legally.
E. WHAT ARE THE COSTS OF NOT RETURNING INCIDENTAL
FINDINGS?
While returning incidental findings is a costly endeavor, a
researcher’s failure to return an incidental finding can also impose costs on the health care system and the research enterprise. To illustrate these potential costs, one should return to
the hypothetical in the introduction. If Sandy Cohen underwent
genomic sequencing for research, but the researchers did not
return her BRCA1 incidental finding, and Sandy discovers several years later that she has breast cancer—what are the implications for society and for the research enterprise?
One cost to society could be increased costs on the health
care system. It is possible that if participants are given incidental findings then they could seek preventative treatment

189.
190.
191.
192.
193.

Christensen et al., supra note 171.
Id. at 526–27.
Id. at 527.
Id. at 527–28.
Id. at 528.
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194

that could avoid major costs down the road. Delaying treatment can impose additional costs on the health care system due
to additional testing; more drastic medical care, such as surgeries or operations that may have been preventable if the disease
had been caught earlier; and increased hospital stays and
treatment. These costs are very difficult to quantify, and it is
not always clear that the incidental finding will provide an opportunity for preventative care or that a participant would undergo preventative care, even if the care were available.
Not only could not returning incidental findings lead to
costs for society in general, but not returning findings can also
lead to direct costs to the research enterprise. One such cost
may be the loss of the public’s trust in the research enterprise.
195
Loss of trust can lead to fewer research participants. Several
studies have concluded that most participants want to know
196
these research results and may feel some entitlement to re197
ceive these results. Thus, the failure to return incidental findings can lead to bad publicity for the research enterprise. Bad
publicity, loss of trust, and lack of reciprocity may have cost
implications for the research enterprise and may threaten the
sustainability of genomics and genetics research as fewer individuals decide to participate in these studies. Although these
costs are nearly impossible to quantify, the cost of not returning incidental findings should be considered as researchers determine what incidental findings should be returned to participants.
This Part has shown that offering to returning incidental
194. See, e.g., Jolie, supra note 6 (describing Angelina Jolie’s story of undergoing a preventative double mastectomy after her doctors discovered she
had a BRCA1 mutation).
195. Cf. Beskow et al., supra note 141, at 492 (arguing that for scientists
who maintain genomic biobanks, “trust . . . is essential to their continued existence”).
196. See, e.g., Caroline Savage Bennette et al., Return of Incidental Findings in Genomic Medicine: Measuring What Patients Value—Development of
an Instrument to Measure Preferences for Information from Next-Generation
Testing (IMPRINT), 15 GENETICS MED. 873, 873 (2013) (investigating participants’ preferences for incidental findings); Juli Murphy Bollinger et al., Public
Preferences Regarding the Return of Individual Genetic Research Results:
Findings from a Qualitative Focus Group Study, 14 GENETICS MED. 451, 452
(2012) (finding that most participants wanted their individual research results). But see Clayton & McGuire, supra note 14, at 474 (“It is also difficult to
assess participants’ general preferences regarding return of results when it is
not clear what specific results might become available.”).
197. See Bollinger et al., supra note 196, at 453 (“For many, the desire . . .
appeared to be related to a sense of ownership, i.e., that information about
their genes belongs to them.”).
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findings is costly on the research enterprise, but not offering to
return these findings can also impose costs. Although many
commentators cite costs of returning incidental findings as a
major concern, these costs are not well understood and current
data on the costs to offer incidental findings in genetics and genomics research is lacking. Until more data is available, however, genetics and genomics researchers find themselves in a
difficult situation. With limited funding and scarce resources,
genetics and genomics researchers need guidance to allocate
resources efficiently while complying with their ethical and legal obligations. Part III of this Note proposes a responsible default rule and much-needed guidance to assist genetics and genomics researchers in their decision to offer or not offer
incidental findings to research participants.
III. DEFINING AN ETHICALLY, LEGALLY, AND FISCALLY
RESPONSIBLE DEFAULT RULE
Policymakers making ethical recommendations to medical
researchers must consider the cost and legal implications of
their recommendations. As analyzed above, the issue of returning incidental findings to research participants is a complex
and multi-faceted problem. Questions about what should be returned, who should return results, who should pay for the returning, and how long a duty extends require serious consideration by policymakers. Any proposed recommendations for
genetics and genomics researchers encompass ethical, legal,
cost, and societal issues that require further research and evaluation. But, in the face of limited data and research on the cost
of returning incidental findings to participants, policymakers
need to give guidelines that allow researchers to fulfill the purpose of their research without overburdening the research enterprise. Sections A through E will address the distinct questions presented above as to what incidental findings should be
returned, who should return the findings, who should pay, how
long a duty to return should last, and what are the costs of not
returning. Section F will provide a default rule and explain how
this default places minimal burdens on researchers and provides much needed guidance and security from the threat of future legal liability.
A. WHAT INCIDENTAL FINDINGS SHOULD BE OFFERED WILL
DEPEND ON THE RESEARCH STUDY
What results should be returned is a complex question that
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encapsulates other complicated issues. Informed consent, analytical verification of results, actionability of results, and the
duty to search for incidental findings make it difficult for researchers to know what results should be offered to participants and what the cost of offering and returning those results
will be. In general, policymakers should keep in mind that the
goal of medical research is to produce generalizable
199
knowledge.
Federal regulations require researchers to acquire in200
formed consent. Although this is a costly process, it is re201
quired both ethically and legally. Researchers should prepare
their study in a way to ensure adequate informed consent,
while still keeping the cost of informed consent manageable.
Researchers should address the possibility of incidental findings with participants up front in order to prevent the cost of
reconsent later. Informed consent may be costly, but because it
is required, researchers must abide by the Common Rule while
managing the costs of informed consent to avoid hobbling the
202
research study budget.
Whether research results must be verified in a CLIAcertified lab is also a complex issue facing researchers and one
203
that requires more research. But, whether CLIA certification
is required does not negate the need for researchers to confirm
the analytical validity of their results. This confirmation is
needed to prevent undue harm to participants from false posi204
tives or other inaccurate results. Like informed consent, analytical verification is not a cost that can be avoided but is rather a cost to be accounted for and managed.
Another issue facing genetics and genomics researchers is
the difficulty of predicting how many incidental findings they
may uncover in their research and whether these results are
205
actionable. While policymakers have published recommendations for what should be returned, issues surrounding
actionability make these obligations less than clear. This ambiguity raises legal concerns as different standards of care can

198. See supra Part II.A.
199. See Ulrich, supra note 18, at 128.
200. Requirements for Informed Consent, 45 C.F.R. § 46.116 (2014).
201. See supra Part II.A.1.
202. See Clayton & McGuire, supra note 14, at 475.
203. See supra Part II.A.2.
204. Criteria for IRB Approval of Research, 45 C.F.R. § 46.111 (2014), requires that researchers minimize potential risks to participants.
205. See supra Part II.A.3.
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evolve from different definitions of “actionable.” Recognizing
this danger, policymakers should leave it to researchers to decide what is actionable as this definition varies by context and
research studies. Researchers should define what is actionable
for the study and explain this to participants in the informed
consent process. As long as researchers define actionability for
their particular study and provide this information to participants, researchers should not be subjected to legal liability
down the road for not adopting a different definition of
actionability.
Finally, researchers should not have a duty to search or
hunt for incidental findings. Such a duty would be overly burdensome and would push researchers’ duties beyond the duties
of clinicians, which have historically been more expansive than
206
the duties of researchers. An ethical duty to search for incidental findings would likely evolve into a legal duty, which will
put more strain on the research enterprise. The benefits of
searching for incidental findings should outweigh the costs of
searching. While it looks like current costs are prohibitive,
more research would help researchers and policymakers understand the implications of ethical recommendations to search.
B. WHO SHOULD OFFER TO RETURN INCIDENTAL FINDINGS MAY
VARY BY STUDY
Who returns incidental findings to research participants is
an important question that has potential legal ramifications as
those who return the results may open themselves up to legal
liability down the road if they fail to adequately return the in207
cidental findings. Unfortunately, given the variety of research
study designs and researchers’ expertise and knowledge in genetics and genomics, a one-size-fits-all approach is unlikely to
be appropriate to resolve the question of who should return the
results.
Researchers are likely to be the most qualified to determine their own resources and abilities to return incidental findings. Thus, researchers should address this issue prior to applying for funding. They should consider who can best bear the
cost and responsibility of returning incidental findings while
still providing participants with the information necessary to
make informed choices about their health care. Whether the researchers offer to return the results or additional personnel are
206. See Clayton & McGuire, supra note 14, at 475–76.
207. See supra Part II.B.
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hired for the task, researchers must ensure that they are giving
participants adequate information while still managing the
costs of the research project.
C. COSTS OF RETURNING INCIDENTAL FINDINGS ARE LIKELY TO
FALL ONTO RESEARCHERS
Who should pay is an interesting question, because unlike
in the medical profession, where costs are usually shifted to insurance companies, the research enterprise cannot always turn
to insurers to cover additional costs. Researchers usually bear
the costs of returning incidental findings to participants, meaning researchers either include the costs in their proposal for research funding or find other means by which to pay. Also, the
cost to offer and return incidental findings is extremely difficult
to calculate and thus, it is difficult for researchers to predict
what costs they will face. As highlighted above, assigning the
costs to researchers and the research enterprise could have a
detrimental effect on the research enterprise. When giving ethical recommendations, policymakers need to remember that the
costs to return incidental findings will likely be borne by researchers.
D. THE DUTY TO OFFER AND RETURN INCIDENTAL FINDINGS
SHOULD BE LIMITED
A duty to return incidental findings should not extend past
the research period. Furthermore, researchers should not have
a duty to recontact participants to offer incidental findings. Researchers, however, should not be barred from recontacting prior research participants and offering to return results. But, researchers should be wary of doing so, as this could become the
standard of care in the industry and could thus expose researchers to liability. Recontacting prior participants poses its
own costs and challenges, and these challenges vary by re208
search design and can be hard to predict. Thus, policymakers
should be explicit in their recommendations that researchers do
not have a duty to return findings beyond the research period
and have no duty to recontact participants.
E. THE COSTS OF NOT OFFERING AND RETURNING RESULTS
MAY BE SIGNIFICANT
The costs of not returning should be included in the determination of whether to return incidental findings. First, the re208. See supra Part II.D.
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searcher should look at what the potential is for an individual
to use this information to prevent increased health care costs in
209
the future. Furthermore, researchers should be cognizant of
how not returning findings can potentially lead to bad publicity
210
for the research enterprise. Bad publicity may result in reduced trust in the research enterprise and fewer individuals
who are willing to participate in genetics and genomics research. These costs will likely depend on the actionability and
211
pathogenicity of the incidental finding and thus these factors
should be taken into account.
F. A RESPONSIBLE DEFAULT FOR GENETICS AND GENOMICS
RESEARCHERS
Several previous recommendations divide the decision to
return into three bins: should return, may return, and should
212
not return. While this approach helps to provide some guidance to researchers, a default rule that recognizes and accounts
for the cost implications of returning and not returning incidental findings is needed. A default rule should ensure that researchers satisfy their ethical responsibilities without imposing
unnecessary threats of legal liability or overly burdening the
research enterprise with unsustainable costs that will threaten
the goal of genetics and genomics research—to “pursue general213
izable knowledge that will benefit society.”
This proposed default rule requires that researchers offer
to return the incidental findings to the research participant.
But if the researcher weighs the costs and benefits of returning
the results with the costs and benefits of not returning the incidental finding and concludes that the costs of returning the
results outweighs the costs of not returning, then she should
have no responsibility to offer the incidental finding to the participant.

209. While this calculation is very similar to whether the incidental finding
is actionable, this takes actionability and looks at it from the standpoint of society as a whole and how the return of an incidental finding can reduce costs
on society, not just the participant.
210. See supra Part II.E.
211. Pathogenicity is the ability to cause a disease.
212. See, e.g., Jonathan S. Berg et al., Deploying Whole Genome Sequencing
in Clinical Practice and Public Health: Meeting the Challenge One Bin at a
Time, 13 GENETICS MED. 499, 501 (2011); Fabsitz et al., supra note 147, at
579.
213. Ulrich, supra note 18, at 128.
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Figure 1. Decision to return scale: Weighing the costs and
benefits to return or not return.

Cost to
Return

Costs Not
to Return

Informed Consent

Potential Increased
Health Costs

Verifying Results

Negative Publicity

Personnel to Return

Loss of Trust

Less Funds for
Research

Reputational Costs

Figure 1 shows the weighing of the costs and benefits of
the decision to return or not return incidental findings to re214
search participants. This approach takes into account the
ethical, legal, and cost implications of returning or not returning incidental findings. Sometimes, the costs of returning due
to lack of information about the actionability and the low benefit of possible preventive care will tip the scale to not return.
Other times, however, the incidental finding may be easily verified and not overly burdensome to return, and by not returning
the results, the researcher risks high reputational costs to the
research enterprise, increased loss of trust, and increased future costs to the health care system. In these cases, the researcher should offer to return the incidental findings to the
participant.
Weighing the costs and benefits on either side is not an
easy task, but the researcher should merely have the burden of
showing that her decision to return or not to return was reasonable. The researcher should, however, bear the burden because she is best equipped to make a determination as to
whether it is better to return or not to return. Given the current legal system, researchers should not be surprised or overwhelmed by this burden, as the legal system often places the
214. Note that not all of the costs and benefit considerations are included
in Figure 1. Figure 1 serves as a visual representation of how the balancing
should work. Furthermore, these costs and benefits are fluid calculations that
will likely vary significantly depending on the study.
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burden on the party that has the most information and has the
215
best ability to make an informed decision.
This default rule not only provides much needed guidance
to researchers, but it may also provide security from the threat
of legal liability. If courts begin to allow negligence claims
against researchers for failure to offer incidental findings, this
default rule will provide strong evidence that the researcher
was reasonable in her decision not to offer incidental findings.
The default rule provides a process by which the researcher can
show that she weighed the costs and benefits of returning and
not returning incidental findings to research participants, and,
thus, her decision not to return the findings was not based on a
negligent act, but rather a well-informed, reasonably grounded
basis.
CONCLUSION
Returning incidental findings to research participants, like
Sandy Cohen, continues to be a hotly contested issue. Although
no federal or state laws currently regulate the disclosure of
these findings, the threat of legal liability is growing as more
lawsuits are being brought against researchers, and as ethical
recommendations are published and begin to establish a standard of care. The cost implications of the legal liability and the
ambiguity surrounding potential liability raise serious concerns
for researchers and society as a whole as the goal of medical research is to promote the benefit of society through the discovery
of scientific, generalizable knowledge.
Policymakers need to recognize the potential for legal liability and need to consider the purpose of genetics and genomics research and the costs imposed on researchers by requiring disclosure of incidental findings. The cost of this duty is
difficult to calculate and will likely vary substantially depending on the particular study. This Note illuminates the urgent
need for more empirical research on the costs implicated by returning incidental findings in genomics and genetics research.
Furthermore, this Note provides an ethically, legally, and fiscally responsible default rule for the return of incidental findings. The default rule places a minimal burden on researchers
and also provides guidance and a sense of security from the
215. Cf. RESTATEMENT (THIRD) OF TORTS: APPORTIONMENT LIABILITY § 8
(AM. LAW INST. 2000) (“Factors assigning percentages of responsibility . . . include (a) the nature of the person’s risk-creating conduct, including any
awareness or indifference with respect to the risks created by the conduct
. . . .”).
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